Critical appraisal of bivalirudin versus heparin for percutaneous coronary intervention: A meta-analysis of randomized trials

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Bavry, Anthony A ^a,b   Elgendy, Islam Y ^b   Mahmoud, Ahmed ^b   Jadhav, Manoj P ^b   Huo, Tianyao ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HIRULOG; BIVALIRUDIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEALTH HAZARD; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; COMPARATIVE STUDY; DOSE RESPONSE; HEMORRHAGE; STENT; THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84930227316     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127832     Document Type: Article

References (56)

1. Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol. 2011; 57: 1190-1199. doi: 10.1016/j.jacc.2010.10.030 PMID: 21371635
2. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289: 853-863. PMID: 12588269
3. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58: e44-122. doi: 10.1016/j.jacc.2011.08.007 PMID: 22070834
4. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010; 31: 2501-2555. doi: 10.1093/eurheartj/ehq277 PMID: 20802248
5. Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014; 384: 599-606. doi: 10.1016/S0140-6736(14)61216-2 PMID: 25131979
6. Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, et al. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2014; 114: 250-259. doi: 10.1016/j.amjcard.2014.04.033 PMID: 24890986
7. Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006; 47: 2364-2373. PMID: 16781360
8. Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. 2011; 365: 1980-1989. doi: 10.1056/NEJMoa1109596 PMID: 22077909
9. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358: 2218-2230. doi: 10.1056/NEJMoa0708191 PMID: 18499566
10. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002; 143: 847-853. PMID: 12040347
11. Tavano D, Visconti G, D'Andrea D, Focaccio A, Golia B, Librera M, et al. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol. 2009; 104: 1222-1228. doi: 10.1016/j.amjcard.2009.06.035 PMID: 19840566
12. Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, et al. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2014; 35: 2285-2294. doi: 10.1093/eurheartj/ehu182 PMID: 24816809
13. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355: 2203-2216. PMID: 17124018
14. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J. 2002; 143: 229-234. PMID: 11835024
15. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med. 1995; 333: 764-769. PMID: 7643883
16. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation. 1995; 91: 2132-2139. PMID: 7697841
17. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. 1993; 87: 1622-1629. PMID: 8491018
18. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2008; 52: 807-814. doi: 10.1016/j.jacc.2008.05.036 PMID: 18755342
19. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001; 142: 952-959. PMID: 11717596
20. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011; 377: 2193-2204. doi: 10.1016/S0140-6736(11)60764-2 PMID: 21665265
21. Anand SX, Kim MC, Kamran M, Sharma SK, Kini AS, Fareed J, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol. 2007; 100: 417-424. PMID: 17659921
22. Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002; 143: 585-593. PMID: 11923794
23. Lev EI, Patel R, Karim A, Kleiman A, Badimon JJ, Kleiman NS. Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study. Thromb Haemost. 2006; 95: 441-446. PMID: 16525571
24. Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, et al. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol. 2007; 27: 1850-1856. PMID: 17525363
25. Saucedo JF, Aude W, Pacheco R, Thorn B, Matin Z, Husain K, et al. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study). Am J Cardiol. 2005; 95: 1453-1456. PMID: 15950569
26. Sibbing D, Busch G, Braun S, Jawansky S, Schomig A, Kastrati A, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J. 2008; 29: 1504-1509. doi: 10.1093/eurheartj/ehn195 PMID: 18467322
27. Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003; 15: 611-616. PMID: 14608128
28. Schulz S, Mehilli J, Neumann FJ, Schuster T, Massberg S, Valina C, et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J. 2010; 31: 2482-2491. doi: 10.1093/eurheartj/ehq330 PMID: 20805113
29. Valgimigli M; for the MATRIX group. Bivalirudin infusion compared to unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: results from the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) Anti-Thrombin program. Presented at ACC.15, 16 March 2015, San Diego, California. Late-breaking Clinical Trials Session #410-12. Available: http://www.abstractsonline.com/pp8/#!/3658/presentation/37595. Accessed 20 March 2015.
30. Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs. heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015 Mar 16. doi: 10.1001/jama.2015.2323
31. Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, et al. Novel approaches for preventing or limiting events (NAPLES) III Trial. Randomised comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Intervent. 2015; 8: 414-423.
32. Feldman A, Suleiman K, Bushari L, Yahalom M, Rozner E, Freedberg NA, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients at high risk for bleeding. Int J Angiol. 2014; 23: 227-232. doi: 10.1055/s-0034-1372244 PMID: 25484553
33. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014; 384: 1849-1858. doi: 10.1016/S0140-6736(14)60924-7 PMID: 25002178
34. Zeymer U, van 't Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J. 2014; 35: 2460-2467. doi: 10.1093/eurheartj/ehu214 PMID: 24849104
35. Xiang DC, Gu XL, Song YM, Huang WJ, Tang LQ, Yin YH, et al. Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention. Chin Med J (Engl). 2013; 126: 3064-3068. PMID: 23981613
36. Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III). J Interv Cardiol. 2013; 26: 107-113. doi: 10.1111/joic.12005 PMID: 23240743
37. Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macri M, Dicuonzo G, et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). Am J Cardiol. 2012; 110: 478-484. doi: 10.1016/j.amjcard.2012.04.017 PMID: 22583760
38. Parodi G, Migliorini A, Valenti R, Bellandi B, Signorini U, Moschi G, et al. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial). Am J Cardiol. 2010; 105: 1053-1059. doi: 10.1016/j.amjcard.2009.12.001 PMID: 20381652
39. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008; 359: 688-696. doi: 10.1056/NEJMoa0802944 PMID: 18703471
40. Deshpande NV, Pratiti R, Admane P, Mukherjee D, Mardikar HM. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention. Indian Heart J. 2012; 64: 444-448. doi: 10.1016/j.ihj.2012.07.022 PMID: 23102380
41. Moliterno DJ; TENACITY Steering Committee and Investigators. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc Interv. 2011; 77: 1001-1009. doi: 10.1002/ccd.22876 PMID: 21598351
42. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007; 369: 907-919. PMID: 17368152
43. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, et al.; REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004; 93: 1092-1096. PMID: 15110198
44. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356: 1020-1029. PMID: 17296821
45. Higgins JP, Deeks JJ, Altman DG. 16.9.5 Validity of methods of meta-analysis for rare events. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011. Available: http://hiv.cochrane.org/sites/hiv.cochrane.org/files/uploads/Ch16-Specialstatistics.pdf. Accessed 29 July 2014.
46. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27: 335-371. PMID: 2858114
47. Shuster JJ, Guo JD, Skyler JS. Meta-analysis of safety for low event-rate binomial trials. Res Synth Methods. 2012; 3. doi: 10.1002/jrsm.1039
48. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560. PMID: 12958120
49. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006; 25: 3443-3457. PMID: 16345038
50. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535. doi: 10.1136/bmj.b2535 PMID: 19622551
51. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001; 323: 42-46. PMID: 11440947
52. Cassese S, Byrne RA, Laugwitz KL, Schunkert H, Berger PB, Kastrati A. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention. 2014 Aug 8. pii: 20140729e. doi: 10.4244/EIJY14M08-01 PMID: 25102830
53. Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al.; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369: 2207-2217. doi: 10.1056/NEJMoa1311096 PMID: 24171490
54. Bertrand OF, Jolly SS, Rao SV, Patel T, Belle L, Bernat I, et al. Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention. Am J Cardiol. 2012; 110: 599-606. doi: 10.1016/j.amjcard.2012.03.051 PMID: 22591669
55. Eslam RB, Reiter N, Kaider A, Eichinger S, Lang IM, Panzer S. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J. 2009; 30: 1831-1836. doi: 10.1093/eurheartj/ehp186 PMID: 19468011
56. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000; 53: 1119-1129. PMID: 11106885